Atrium Therapeutics, Inc. (RNA)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
8.21 USD
-0.19
(-2.262%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:56 a.m. EDT
Atrium Therapeutics presents a stark picture of a distressed biotech asset with no immediate catalyst for recovery. Fundamentally, the company is bleeding cash with negative operating margins and shrinking revenue, sitting well below its book value due to a lack of profitability. The balance sheet, while currently liquid, faces an existential threat given the severe cash burn and the absence of any revenue growth trajectory to fund operations. The market has clearly priced in this deterioration, evidenced by the crushing pressure in the options chain where buyers are aggressively stacking protection at strikes far below the current price, while sellers are virtually absent. With no dividend to provide income and a statistical forecast leaning slightly negative, there is no compelling case for a short-term bounce or a long-term turnaround based on the current data. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.158565 |
| AutoARIMA | 0.165549 |
| AutoETS | 0.165698 |
| MSTL | 0.165919 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 5.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.164 |
| Excess Kurtosis | -1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.784 |
| Revenue per Share | 2.095 |
| Market Cap | 140,437,344 |
| Forward P/E | -1.02 |
| Profit Margins | -184.15% |
| Website | https://atriumtherapeutics.com |
As of Oct. 10, 2026, 7:56 a.m. EDT: Speculators are overwhelmingly bearish, positioning massive volume in deep out-of-the-money puts (strikes 65-70) relative to negligible call activity. This heavy put flow suggests a strong expectation of further downside or a desire to hedge against significant losses, while the lack of call interest indicates a lack of speculative bullishness despite the high implied volatility environment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44338983 |
| Address1 | 10,578 Science Center Drive |
| Address2 | Suite 125 |
| All Time High | 16.77 |
| All Time Low | 7.63 |
| Ask | 10.49 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 299,860 |
| Average Daily Volume3 Month | 256,175 |
| Average Volume | 256,175 |
| Average Volume10Days | 299,860 |
| Bid | 8.06 |
| Bid Size | 6 |
| Book Value | 12.544 |
| City | San Diego |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.21 |
| Current Ratio | 8.73 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.4815 |
| Day Low | 8.21 |
| Debt To Equity | 0.784 |
| Display Name | Atrium Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -68,528,000 |
| Ebitda Margins | -1.91221 |
| Enterprise To Ebitda | 1.777 |
| Enterprise To Revenue | -3.398 |
| Enterprise Value | -121,779,672 |
| Eps Current Year | -4.55 |
| Eps Forward | -8.06 |
| Eps Trailing Twelve Months | -5.44 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.0018 |
| Fifty Day Average Change | -2.7917995 |
| Fifty Day Average Change Percent | -0.25375843 |
| Fifty Two Week Change Percent | -44.33898 |
| Fifty Two Week High | 16.77 |
| Fifty Two Week High Change | -8.56 |
| Fifty Two Week High Change Percent | -0.5104353 |
| Fifty Two Week Low | 7.63 |
| Fifty Two Week Low Change | 0.5799999 |
| Fifty Two Week Low Change Percent | 0.07601572 |
| Fifty Two Week Range | 7.63 - 16.77 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,772,202,600,000 |
| Float Shares | 15,043,558 |
| Forward Eps | -8.06 |
| Forward P E | -1.0186104 |
| Full Exchange Name | NasdaqGS |
| Fullday Change | -0.18999958 |
| Fullday Change Percent | -2.2592103 |
| Fullday Price | 8.21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.56366 |
| Gross Profits | -20,200,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0416 |
| Held Percent Institutions | 0.84556997 |
| Implied Shares Outstanding | 17,105,643 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-02-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. |
| Long Name | Atrium Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 140,437,344 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1972622727 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -65,992,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 142,318,949 |
| Number Of Analyst Opinions | 4 |
| Open | 8.4 |
| Operating Cashflow | -53,188,000 |
| Operating Margins | -7.52929 |
| Phone | 619 876 0700 |
| Previous Close | 8.4 |
| Price Eps Current Year | -1.8043956 |
| Price Hint | 2 |
| Price To Book | 0.6544962 |
| Price To Sales Trailing12 Months | 3.9187808 |
| Profit Margins | -1.8414501 |
| Quick Ratio | 8.376 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -2.2619 |
| Regular Market Day High | 8.4815 |
| Regular Market Day Low | 8.21 |
| Regular Market Day Range | 8.21 - 8.4815 |
| Regular Market Open | 8.4 |
| Regular Market Previous Close | 8.4 |
| Regular Market Price | 8.21 |
| Regular Market Time | 1,791,835,200 |
| Regular Market Volume | 87,242 |
| Revenue Growth | -0.219 |
| Revenue Per Share | 2.095 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,105,643 |
| Shares Percent Shares Out | 0.1985 |
| Shares Short | 3,395,873 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,351,526 |
| Short Name | Atrium Therapeutics, Inc. |
| Short Ratio | 8.4 |
| Source Interval | 15 |
| State | CA |
| Symbol | RNA |
| Target High Price | 25.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 25.0 |
| Total Cash | 263,900,000 |
| Total Cash Per Share | 15.428 |
| Total Debt | 1,683,000 |
| Total Revenue | 35,837,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.437962 |
| Two Hundred Day Average Change | -4.2279615 |
| Two Hundred Day Average Change Percent | -0.33992398 |
| Type Disp | Equity |
| Volume | 87,242 |
| Website | https://atriumtherapeutics.com |
| Zip | 92,121 |